论文部分内容阅读
2014年8月,美国FDA批准Belsomra(suvorexant)治疗入睡及睡眠困难(失眠症)患者。本品是一种食欲素受体拮抗剂,是该类药物中首个获批药物。食欲素是参与调节醒睡周期的化学物质,在保持觉醒方面起重要作用。本品可改变食欲素在大脑中的信息行为。失眠症患者入睡或睡眠困难,其疾病程度取决于失眠症的发生频次和时间长度。失眠症可引起白天嗜睡,使人缺乏精力、焦虑、抑郁或烦躁。失眠症患者可能存在注意力、学习及记忆方面的困难。
In August 2014, the U.S. FDA approved Belsomra (suvorexant) for patients who fall asleep and have difficulty sleeping (insomnia). This product is an orexin receptor antagonist, is the first of these drugs approved drugs. Orexins, chemicals involved in the regulation of the sleep-wake cycle, play an important role in keeping awake. This product can change the behavior of orexin in the brain. Insomnia patients sleep or sleep difficulties, the extent of their disease depends on the frequency and duration of insomnia. Insomnia can cause daytime drowsiness, deprivation of energy, anxiety, depression or irritability. Insomnia patients may have attention, learning and memory difficulties.